{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T09:29:44Z","timestamp":1768901384541,"version":"3.49.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.clinthera.2018.01.002","type":"journal-article","created":{"date-parts":[[2018,2,10]],"date-time":"2018-02-10T01:09:23Z","timestamp":1518224963000},"page":"309-319","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Methotrexate Dose in Patients With Early Rheumatoid Arthritis Impacts Methotrexate Polyglutamate Pharmacokinetics, Adalimumab Pharmacokinetics, and Efficacy: Pharmacokinetic and Exposure-response Analysis of the CONCERTO Trial"],"prefix":"10.1016","volume":"40","author":[{"given":"Sandra L.","family":"Goss","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheri E.","family":"Klein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziyi","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles S.","family":"Locke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramona C.","family":"Rodila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hartmut","family":"Kupper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerd-Rudiger","family":"Burmester","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walid M.","family":"Awni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2018.01.002_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.39480","article-title":"2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.clinthera.2018.01.002_bib2","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2018.01.002_bib3","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1093\/rheumatology\/XXXIV.suppl_2.43","article-title":"Efficacy of methotrexate in rheumatoid arthritis","volume":"34","author":"Weinblatt","year":"1995","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.clinthera.2018.01.002_bib4","first-page":"473","article-title":"Methotrexate in rheumatoid arthritis","volume":"58","author":"Swierkot","year":"2006","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.clinthera.2018.01.002_bib5","first-page":"2551","article-title":"Antiproliferative and antiinflammatory effects of methotrexate on cultured differentiating myeloid monocytic cells (THP-1) but not on synovial macrophages from patients with rheumatoid arthritis","volume":"27","author":"Cutolo","year":"2000","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clinthera.2018.01.002_bib6","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1093\/rheumatology\/keq216","article-title":"Red blood cell methotrexate polyglutamates emerge as a function of dosage intensity and route of administration during pulse methotrexate therapy in rheumatoid arthritis","volume":"49","author":"Dervieux","year":"2010","journal-title":"Rheumatology"},{"key":"10.1016\/j.clinthera.2018.01.002_bib7","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/s11926-010-0120-3","article-title":"Measurement of erythrocyte methotrexate polyglutamate levels: ready for clinical use in rheumatoid arthritis?","volume":"12","author":"Danila","year":"2010","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.clinthera.2018.01.002_bib8","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1056\/NEJM200011303432201","article-title":"A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis","volume":"343","author":"Bathon","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2018.01.002_bib9","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.1002\/art.20568","article-title":"Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial","volume":"50","author":"St Clair","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2018.01.002_bib10","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.21519","volume":"54","author":"Breedveld","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2018.01.002_bib11","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(08)61000-4","article-title":"Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial","volume":"372","author":"Emery","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2018.01.002_bib12","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1002\/art.30263","article-title":"The effects of golimumab on radiographic progression in rheumatoid arthritis: results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy","volume":"63","author":"Emery","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2018.01.002_bib13","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1093\/rheumatology\/kes150","article-title":"Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study","volume":"51","author":"Weinblatt","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.clinthera.2018.01.002_bib14","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W","article-title":"Therapeutic efficacy of multiple intravenous infusions of anti- tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis","volume":"41","author":"Maini","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2018.01.002_bib15","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1136\/ard.2005.049858","article-title":"High levels of human anti-human antibodies to adalimumab in a patient not responding to adalimumab treatment","volume":"65","author":"Bartelds","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinthera.2018.01.002_bib16","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1136\/ard.2006.065615","article-title":"Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis","volume":"66","author":"Bartelds","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinthera.2018.01.002_bib17","unstructured":"Humira (adalimumab) [US prescribing information]. North Chicago, IL; AbbVie, 2017."},{"key":"10.1016\/j.clinthera.2018.01.002_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003088-197803010-00001","article-title":"Clinical pharmacokinetics of methotrexate","volume":"3","author":"Shen","year":"1978","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2018.01.002_bib19","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1002\/art.24034","article-title":"Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis","volume":"58","author":"Dalrymple","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2018.01.002_bib20","first-page":"1709","article-title":"Patients with rheumatoid arthritis treated with methotrexate (MTX): concentrations of steady-state erythrocyte MTX correlate to plasma concentrations and clinical efficacy","volume":"35","author":"Hornung","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clinthera.2018.01.002_bib21","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1136\/annrheumdis-2013-203725","article-title":"Methotrexate polyglutamates in erythrocytes are associated with lower disease activity in patients with rheumatoid arthritis","volume":"74","author":"de Rotte","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinthera.2018.01.002_bib22","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/S0149-2918(03)80164-9","article-title":"Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study","volume":"25","author":"Weisman","year":"2003","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2018.01.002_bib23","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1136\/annrheumdis-2013-204769","article-title":"Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial","volume":"74","author":"Burmester","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinthera.2018.01.002_bib24","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/jdv.13884","article-title":"Impact of immunogenicity on pharmacokinetics, efficacy and safety of adalimumab in adult patients with moderate to severe chronic plaque psoriasis","volume":"31","author":"Mostafa","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clinthera.2018.01.002_bib25","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1007\/s40262-016-0502-4","article-title":"Population pharmacokinetics and immunogenicity of adalimumab in adult patients with moderate-to-severe hidradenitis suppurativa","volume":"56","author":"Nader","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2018.01.002_bib26","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1093\/rheumatology\/28.5.422","article-title":"Synovial and serum levels of methotrexate during methotrexate therapy of rheumatoid arthritis","volume":"28","author":"Tishler","year":"1989","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.clinthera.2018.01.002_bib27","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1002\/art.20460","article-title":"Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis","volume":"50","author":"Dervieux","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2018.01.002_bib28","doi-asserted-by":"crossref","first-page":"4881","DOI":"10.1073\/pnas.82.15.4881","article-title":"Inhibition of phosphoribosylaminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates","volume":"82","author":"Allegra","year":"1985","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291818300031?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291818300031?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,2]],"date-time":"2018-10-02T01:10:42Z","timestamp":1538442642000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291818300031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["S0149291818300031"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2018.01.002","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Methotrexate Dose in Patients With Early Rheumatoid Arthritis Impacts Methotrexate Polyglutamate Pharmacokinetics, Adalimumab Pharmacokinetics, and Efficacy: Pharmacokinetic and Exposure-response Analysis of the CONCERTO Trial","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2018.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}